Half of NCI Cancer Center Physician Directors Received Industry Payments in 2017
August 6th 2019In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.
Multiple Primary Tumors Over a Lifetime
July 16th 2019The risk of multiple primary cancers is increasing due to increasing numbers of survivors, long-term side effects of chemotherapy and/or radiation therapy, increased diagnostic sensitivity, and persisting effects of genetic and behavioral risk factors.
Chemo Brain in Cancer Patients: What Is It and How Can It Be Managed?
June 24th 2019Many patients complain of "chemo brain," or a drop in cognitive function during or after receiving chemotherapy, but there are strategies to manage chemo brain, as well as research on how chemotherapy affects the brain long-term.
FDA Approves Polatuzumab Vedotin-Piiq Combination for DLBCL Patients
June 11th 2019The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma.